“ what we believe, what I believe is as we move from a pandemic state, from a pandemic situation to an endemic situation, normal market forces, normal market conditions will start to kick in. And factors like efficacy, booster ability, clinical utility will basically become very important, and we view that as, quite frankly, a significant opportunity for our vaccine from a demand perspective, from a pricing perspective, given the clinical profile of our vaccine. So clearly, more to come here. But we think as this shifts from pandemic to endemic, we think there's an opportunity here for us.”
If you look at the graphs of any nation regarding 2nd doses there is a plateau of people that aren't getting it that stretches for months. Why wouldn't they want a second dose?
You severely underestimate people's laziness. Having to schedule an appointment for a first jab is already an ordeal for most of them, so for a second one? Hell no. A non-negligeable group of people also think that only one jab offers enough protection in the long run (as it is the case for many other vaccines), so they do not bother to get the second one, in spite of scientific evidence.
Still, I wonder where we're going with the number of injections to be done. How many will we need in 2 to 3 years? 5 or 6? And what about people who are late on their jabs? This is gonna be some real mess. I guess the only way out is finding a functional cure for COVID.
I agree with you. I've worked in healthcare and I can attest to that. It is hard to make people do things. Beyond the differences in people's ideology about the vaccine, adherence is a great problem in healthcare.
https://s21.q4cdn.com/317678438/files/doc_downloads/Transcri...
“ what we believe, what I believe is as we move from a pandemic state, from a pandemic situation to an endemic situation, normal market forces, normal market conditions will start to kick in. And factors like efficacy, booster ability, clinical utility will basically become very important, and we view that as, quite frankly, a significant opportunity for our vaccine from a demand perspective, from a pricing perspective, given the clinical profile of our vaccine. So clearly, more to come here. But we think as this shifts from pandemic to endemic, we think there's an opportunity here for us.”